MedTrace Logo

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

NCT00789581 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 614

Last updated 2017-07-02

Study results available
· View outcomes & findings →

Summary

This is a randomized, Phase III, open-label, multicenter study.

Conditions

Interventions

DRUG

Doxorubicin

Doxorubicin 60 mg/m2

DRUG

Cyclophosphamide

Cyclophosphamide 600 mg/m2

DRUG

Ixabepilone (Ixempra)

Ixabepilone 40 mg/m2

DRUG

Paclitaxel (Taxol)

Paclitaxel 80 mg/m2

Sponsors & Collaborators

Principal Investigators

  • Denise A Yardley, M.D. · SCRI Development Innovations, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2015-12-31
Completion
2016-11-30

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00789581 on ClinicalTrials.gov